Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib Monotherapy and with Tislelizumab in HCC or G/GEJ Cancer
NCT03941873Phase 2Completed
- Sponsor
- BeiGene
- Start
- Feb 2019
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sitravatinib in hepatocellular carcinoma (HCC), gastric cancer (GC) and gastroesophageal junction cancer, sponsored by BeiGene. Primary endpoints: Number of Participants With Adverse Events and Objective Response Rate. Started Feb 2019; status: completed.
02
Drugs
sitravatinib
03
Conditions
hepatocellular carcinoma (HCC)gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03941873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941873.